Supplementary Figure 1. Comparative Kaplan–Meier survival curves indicating differences between immunotherapy (IT) and targeted therapy for (A) progression-free survival (PFS), (B) overall survival (OS), and (C) cancer-specific survival (CSS). (A) The PFS Kaplan–Meier curve showed that 14/16 patients experienced disease progression with a median time of 2.85 months, which was significantly different from the 4.8 months of the targeted therapy (TT) group (59/72 patients). (B) The OS curve showed that 100% of patients died with a median time of 10.1 months, which was insignificantly different from the 10.8 months found with the TT group (58/72 patients). (C) The CSS Kaplan–Meier curve showed 12/16 patients died of cancer with a median time of 13.0 months, insignificantly different from the 12.0 months of the TT group (51/72 patients).